About Liminal biosciences
Liminal BioSciences: Pioneering the Future of Biopharmaceuticals
Liminal BioSciences is a biopharmaceutical company that has been making waves in the industry with its innovative approach to drug discovery and development. The company is dedicated to creating novel, small molecule drug candidates that have the potential to revolutionize the way we treat a wide range of diseases.
Founded in 1992, Liminal BioSciences has grown into a leading player in the biopharmaceutical industry. With headquarters in Laval, Quebec, Canada, and offices in Cambridge, Massachusetts and Seattle, Washington, the company has established itself as a global leader in drug discovery and development.
At Liminal BioSciences, their mission is simple: to improve human health by developing innovative therapies for patients suffering from serious diseases. To achieve this goal, they focus on discovering new drugs that target specific disease pathways or mechanisms.
One of their key strengths lies in their expertise in protein biochemistry. This allows them to identify new targets for drug development and design molecules that can interact with these targets with high specificity and potency. They also have extensive experience working with small molecules – compounds that are typically less complex than large biological molecules like proteins – which makes them well-suited for developing drugs that can be taken orally rather than through injection or infusion.
Liminal BioSciences’ pipeline includes several promising drug candidates across multiple therapeutic areas such as respiratory diseases (including cystic fibrosis), liver diseases (such as non-alcoholic steatohepatitis), immunology (including autoimmune disorders), oncology (cancer) and infectious diseases.
One of their most exciting programs is focused on developing treatments for cystic fibrosis (CF). CF is a genetic disorder caused by mutations in the CFTR gene which leads to thick mucus buildup within various organs including lungs causing chronic infections leading ultimately to respiratory failure. There are currently no cures for CF, and existing treatments only address the symptoms of the disease. Liminal BioSciences’ drug candidate, PBI-4050, has shown promising results in preclinical studies by reducing inflammation and fibrosis in the lungs of CF patients.
Another area where Liminal BioSciences is making significant progress is in developing treatments for non-alcoholic steatohepatitis (NASH), a liver disease that affects millions of people worldwide. NASH is characterized by inflammation and scarring of the liver which can lead to cirrhosis or liver cancer. There are currently no approved drugs for NASH, but Liminal BioSciences’ drug candidate, fezagepras (PBI-4547), has shown promising results in preclinical studies by reducing inflammation and fibrosis in the liver.
Liminal BioSciences’ commitment to innovation extends beyond their drug development programs. They have also developed a proprietary technology platform called LimiSphere® which allows them to identify new targets for drug development more efficiently than traditional methods. This platform combines advanced computational modeling with experimental validation techniques to rapidly screen large numbers of potential targets and identify those with the greatest potential for therapeutic benefit.
In addition to their focus on innovation, Liminal BioSciences places a strong emphasis on collaboration. They work closely with academic institutions, research organizations, patient advocacy groups and other biopharmaceutical companies to advance their research programs and bring new therapies to patients as quickly as possible.
Overall, Liminal BioSciences is an exciting company that is at the forefront of biopharmaceutical innovation. With its cutting-edge technology platforms and deep expertise in protein biochemistry and small molecule drug discovery & development they are well-positioned to make significant contributions towards improving human health through novel therapies across multiple therapeutic areas including respiratory diseases (including cystic fibrosis), liver diseases (such as non-alcoholic steatohepatitis), immunology (including autoimmune disorders), oncology (cancer) and infectious diseases.